vilazodone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4223 163521-12-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vilazodone
  • viibryd
  • vilazodone hydrochloride
  • vilazodone HCl
A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT.
  • Molecular weight: 441.54
  • Formula: C26H27N5O2
  • CLOGP: 4.33
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 102.29
  • ALOGS: -3.56
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 4.85 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.76 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 15.66 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.373 Moderate 0.75
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.138 Moderate 0.75
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 25.003 10^-6 cm/s Moderate 0.75
dh-clint Dog hepatocyte intrinsic clearance 29.309 uL/min/10^6 cells Moderate 0.75
dppb Dog plasma protein binding (% unbound) 3.520 % Moderate 0.75
fcs-ppb Fetal calf serum protein binding (% unbound) 12.300 % Moderate 0.75
herg hERG pIC50 5.801 pIC50 Moderate 0.75
hh-clint Human hepatocyte intrinsic clearance 4.111 uL/min/10^6 cells Moderate 0.75
hlm-clint Human liver microsomal intrinsic clearance 36.983 uL/min/mg protein Moderate 0.75
hppb Human plasma protein binding (% unbound) 2.480 % Moderate 0.75
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,ALK,AURKA,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,IKBKB,INSR,IRAK1,ITK,JAK1,JAK2,KDR,KIT,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MARK4,MET,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,SRC,STK33,SYK,TEK,TGFBR1,TTK,ULK1 55
kinase-selectivity-class DYRK1B,MAP2K6,PDK4,SIK2,STK33 5
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 7.762 Moderate 0.75
mh-clint Mouse hepatocyte intrinsic clearance 39.628 Moderate 0.75
mppb Mouse plasma protein binding (% unbound) 2.200 Moderate 0.75
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 11.614 Moderate 0.75
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 6.400 % Moderate 0.75
rh-clint Rat hepatocyte intrinsic clearance 63.826 uL/min/10^6 cells Moderate 0.75
rh-fuinc Rat hepatocyte fraction unbound in incubation 20 % Moderate 0.75
rppb Rat plasma protein binding (% unbound) 1.510 % Moderate 0.75
solubility-dd Solubility at pH 7.4 in DMSO 2.198 uM Moderate 0.75

Approvals:

DateAgencyCompanyOrphan
Jan. 21, 2011 FDA FOREST LABS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 303.77 19.15 136 6783 73719 90547809
Abnormal dreams 146.11 19.15 48 6871 11209 90610319
Hallucination 135.68 19.15 76 6843 65883 90555645
Anxiety 104.18 19.15 123 6796 309649 90311879
Tardive dyskinesia 96.69 19.15 35 6884 10895 90610633
Serotonin syndrome 92.70 19.15 49 6870 37838 90583690
Completed suicide 87.63 19.15 79 6840 144979 90476549
Persistent genital arousal disorder 86.83 19.15 18 6901 682 90620846
Agitation 85.65 19.15 57 6862 67041 90554487
Nightmare 79.63 19.15 37 6882 21688 90599840
Mania 74.26 19.15 31 6888 14093 90607435
Sleep paralysis 71.33 19.15 16 6903 882 90620646
Anger 58.60 19.15 26 6893 13694 90607834
Tremor 54.98 19.15 63 6856 153110 90468418
Crying 53.90 19.15 30 6889 25615 90595913
Suicide attempt 53.40 19.15 45 6874 75354 90546174
Irritability 52.12 19.15 33 6886 35629 90585899
Dissociation 50.18 19.15 19 6900 6696 90614832
Paraesthesia 49.66 19.15 77 6842 250249 90371279
Feeling abnormal 48.92 19.15 62 6857 167173 90454355
Depression 48.21 19.15 84 6835 300517 90321011
Seizure 46.89 19.15 58 6861 152571 90468957
Insomnia 45.64 19.15 87 6832 333387 90288141
Withdrawal syndrome 41.02 19.15 24 6895 22500 90599028
Panic attack 40.03 19.15 25 6894 26340 90595188
Dizziness 39.23 19.15 116 6803 589168 90032360
Electric shock sensation 38.84 19.15 11 6908 1559 90619969
Muscle twitching 34.37 19.15 22 6897 24180 90597348
Hallucination, auditory 29.03 19.15 17 6902 15958 90605570
Product dose omission issue 28.12 19.15 66 6853 291621 90329907
Somnolence 27.88 19.15 54 6865 209030 90412498
Nausea 27.48 19.15 161 6758 1110155 89511373
Product administration interrupted 27.30 19.15 15 6904 12477 90609051
Diarrhoea 27.09 19.15 142 6777 939048 89682480
Pre-existing condition improved 25.69 19.15 13 6906 9156 90612372
Obsessive-compulsive disorder 24.05 19.15 10 6909 4494 90617034
Hypnagogic hallucination 22.92 19.15 5 6914 242 90621286
Homeless 21.39 19.15 4 6915 88 90621440
Aggression 21.13 19.15 17 6902 26651 90594877
Ocular discomfort 20.73 19.15 10 6909 6360 90615168
Mood swings 20.35 19.15 15 6904 20687 90600841
Palpitations 20.31 19.15 37 6882 136691 90484837
Product substitution issue 19.88 19.15 14 6905 17994 90603534
Infusion related reaction 19.58 19.15 4 6915 416776 90204752
Blood pressure increased 19.39 19.15 45 6874 197172 90424356

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 160.66 29.04 68 2126 48093 42571048
Serotonin syndrome 136.86 29.04 51 2143 25794 42593347
Completed suicide 59.52 29.04 45 2149 96420 42522721
Sexual dysfunction 49.48 29.04 17 2177 6758 42612383
Mania 49.17 29.04 19 2175 10528 42608613
Anxiety 43.48 29.04 41 2153 118519 42500622
Irritability 34.04 29.04 20 2174 28108 42591033
Partial seizures 32.54 29.04 12 2182 5847 42613294
Anger 32.34 29.04 15 2179 13003 42606138

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 264.91 20.21 123 6400 93814 110488962
Serotonin syndrome 137.76 20.21 68 6455 59085 110523691
Completed suicide 131.51 20.21 111 6412 242270 110340506
Abnormal dreams 92.54 20.21 33 6490 12747 110570029
Anxiety 91.51 20.21 107 6416 344971 110237805
Persistent genital arousal disorder 86.00 20.21 17 6506 659 110582117
Tardive dyskinesia 83.21 20.21 31 6492 13548 110569228
Hallucination 73.18 20.21 55 6468 101377 110481399
Mania 70.42 20.21 31 6492 20765 110562011
Anger 63.28 20.21 28 6495 18979 110563797
Irritability 58.59 20.21 36 6487 47773 110535003
Sleep paralysis 52.88 20.21 12 6511 906 110581870
Crying 52.39 20.21 27 6496 25601 110557175
Dissociation 51.40 20.21 20 6503 9822 110572954
Tremor 50.66 20.21 61 6462 202171 110380605
Agitation 49.63 20.21 46 6477 113005 110469771
Nightmare 46.94 20.21 29 6494 38834 110543942
Depression 45.30 20.21 73 6450 317262 110265514
Insomnia 44.88 20.21 78 6445 360512 110222264
Suicide attempt 39.55 20.21 39 6484 103355 110479421
Paraesthesia 35.93 20.21 61 6462 276460 110306316
Muscle twitching 35.29 20.21 22 6501 29913 110552863
Product dose omission issue 34.16 20.21 65 6458 321717 110261059
Feeling abnormal 33.50 20.21 47 6476 180664 110402112
Intentional overdose 33.21 20.21 40 6483 132461 110450315
Withdrawal syndrome 29.48 20.21 20 6503 31360 110551416
Product administration interrupted 29.32 20.21 14 6509 11278 110571498
Dizziness 27.52 20.21 97 6426 698096 109884680
Acute kidney injury 27.00 20.21 3 6520 635427 109947349
Seizure 26.37 20.21 47 6476 221138 110361638
Partial seizures 26.24 20.21 13 6510 11336 110571440
Vision blurred 26.07 20.21 35 6488 128987 110453789
Hallucination, auditory 25.21 20.21 17 6506 26380 110556396
Product substitution issue 24.82 20.21 16 6507 23045 110559731
Panic attack 23.80 20.21 17 6506 28923 110553853
Ocular discomfort 23.44 20.21 11 6512 8522 110574254
Obsessive-compulsive disorder 21.97 20.21 10 6513 7231 110575545
Homeless 20.83 20.21 4 6519 133 110582643

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AX24 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
MeSH PA D000928 Antidepressive Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D017366 Serotonin Receptor Agonists
MeSH PA D017367 Selective Serotonin Reuptake Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35941 serotonergic agonist
CHEBI has role CHEBI:50949 serotonin uptake inhibitor
CHEBI has role CHEBI:35474 anxiolytic drug

Related Drugs by ATC class:

N06AX Other antidepressants 28 drugs
agomelatinebifemelanebrexanolonebupropiondesvenlafaxinedextromethorphanduloxetineesketaminegepironelevomilnacipranmedifoxaminemianserin show all 28 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000
Suicidal thoughts contraindication 6471006
Bipolar disorder contraindication 13746004 DOID:3312
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Blood coagulation disorder contraindication 64779008 DOID:1247
Hyponatremia contraindication 89627008
Seizure disorder contraindication 128613002
Suicidal contraindication 267073005
Serotonin syndrome contraindication 371089000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.56 acidic
pKa2 13.13 acidic
pKa3 8.58 Basic
pKa4 1.41 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
5-hydroxytryptamine receptor 1A GPCR AGONIST Ki 9.70 IUPHAR CHEMBL
Sodium-dependent serotonin transporter Transporter INHIBITOR IC50 9.30 IUPHAR CHEMBL
Beta-2 adrenergic receptor GPCR Ki 5.60 CHEMBL
Mu-type opioid receptor GPCR Ki 6.14 CHEMBL
D(2) dopamine receptor GPCR AGONIST IC50 6.18 IUPHAR
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.85 CHEMBL
Sodium-dependent noradrenaline transporter Transporter IC50 6.80 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 7.19 CHEMBL
5-hydroxytryptamine receptor 6 GPCR Ki 6.02 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 5.41 CHEMBL
D(3) dopamine receptor GPCR AGONIST IC50 7.15 IUPHAR
Histamine H1 receptor GPCR AGONIST IC50 6.50 IUPHAR
5-hydroxytryptamine receptor 1B GPCR Ki 5.91 CHEMBL
5-hydroxytryptamine receptor 1D GPCR Ki 6.43 CHEMBL
Sodium-dependent dopamine transporter Transporter IC50 6.53 CHEMBL
D(4) dopamine receptor GPCR Ki 6.08 CHEMBL
5-hydroxytryptamine receptor 4 GPCR AGONIST IC50 6.60 IUPHAR
Adrenergic receptor alpha-2 GPCR IC50 5.22 CHEMBL
Adrenergic receptor alpha-1 GPCR IC50 5.70 CHEMBL
Transmembrane protein 97 Enzyme Ki 5.96 CHEMBL
D(3) dopamine receptor GPCR IC50 7.15 CHEMBL
5-hydroxytryptamine receptor 1D GPCR IC50 5.40 CHEMBL
D(4) dopamine receptor GPCR IC50 5.47 CHEMBL
5-hydroxytryptamine receptor 1B GPCR IC50 5.30 CHEMBL
D(2) dopamine receptor GPCR IC50 6.18 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 9.52 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 9.30 CHEMBL
5-hydroxytryptamine receptor 2A GPCR IC50 5.82 CHEMBL
Acetylcholinesterase Enzyme IC50 4.67 CHEMBL
5-hydroxytryptamine receptor 7 GPCR IC50 5.52 CHEMBL
Acetylcholinesterase Enzyme IC50 4.67 CHEMBL
5-hydroxytryptamine receptor 6 GPCR IC50 5.52 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel IC50 5.37 CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 5.70 CHEMBL
5-hydroxytryptamine receptor 4 GPCR IC50 6.60 CHEMBL

External reference:

IDSource
4030483 VUID
N0000182438 NUI
D09698 KEGG_DRUG
163521-08-2 SECONDARY_CAS_RN
4030483 VANDF
4030484 VANDF
C1530072 UMLSCUI
CHEBI:70707 CHEBI
CHEMBL439849 ChEMBL_ID
CHEMBL1615374 ChEMBL_ID
D000069503 MESH_DESCRIPTOR_UI
DB06684 DRUGBANK_ID
7427 IUPHAR_LIGAND_ID
7638 INN_ID
S239O2OOV3 UNII
6918314 PUBCHEM_CID
1086768 RXNORM
179494 MMSL
27744 MMSL
359491 MMSL
d07740 MMSL
013753 NDDF
013754 NDDF
702837008 SNOMEDCT_US
702838003 SNOMEDCT_US
715638004 SNOMEDCT_US
YG7 PDB_CHEM_ID
S239O2OOV3 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 0456-1110 TABLET 10 mg ORAL NDA 32 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 0456-1120 TABLET 20 mg ORAL NDA 32 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 0456-1140 TABLET 40 mg ORAL NDA 32 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0480-2043 TABLET, FILM COATED 40 mg ORAL ANDA 29 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0480-2044 TABLET, FILM COATED 20 mg ORAL ANDA 29 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0480-2045 TABLET, FILM COATED 10 mg ORAL ANDA 29 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-352 TABLET 10 mg ORAL ANDA 33 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-352 TABLET 10 mg ORAL ANDA 33 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-353 TABLET 20 mg ORAL ANDA 33 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-353 TABLET 20 mg ORAL ANDA 33 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-354 TABLET 40 mg ORAL ANDA 33 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-354 TABLET 40 mg ORAL ANDA 33 sections
VILAZODONE HYDROCHLORIDE Human Prescription Drug Label 1 46708-232 TABLET, FILM COATED 10 mg ORAL ANDA 31 sections
VILAZODONE HYDROCHLORIDE Human Prescription Drug Label 1 46708-233 TABLET, FILM COATED 20 mg ORAL ANDA 31 sections
VILAZODONE HYDROCHLORIDE Human Prescription Drug Label 1 46708-234 TABLET, FILM COATED 40 mg ORAL ANDA 31 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51407-915 TABLET, FILM COATED 10 mg ORAL ANDA 29 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51407-916 TABLET, FILM COATED 20 mg ORAL ANDA 29 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51407-917 TABLET, FILM COATED 40 mg ORAL ANDA 29 sections
vilazodone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60505-4372 TABLET 10 mg ORAL ANDA 29 sections
vilazodone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60505-4373 TABLET 20 mg ORAL ANDA 29 sections
vilazodone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60505-4374 TABLET 40 mg ORAL ANDA 29 sections
VILAZODONE HYDROCHLORIDE Human Prescription Drug Label 1 62332-232 TABLET, FILM COATED 10 mg ORAL ANDA 31 sections
VILAZODONE HYDROCHLORIDE Human Prescription Drug Label 1 62332-233 TABLET, FILM COATED 20 mg ORAL ANDA 31 sections
VILAZODONE HYDROCHLORIDE Human Prescription Drug Label 1 62332-234 TABLET, FILM COATED 40 mg ORAL ANDA 31 sections
vilazodone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68788-8734 TABLET 20 mg ORAL ANDA 29 sections
vilazodone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68788-8734 TABLET 20 mg ORAL ANDA 29 sections
vilazodone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68788-8735 TABLET 40 mg ORAL ANDA 29 sections
vilazodone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68788-8735 TABLET 40 mg ORAL ANDA 29 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 69097-979 TABLET, FILM COATED 10 mg ORAL ANDA 32 sections
Vilazodone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 69097-981 TABLET, FILM COATED 20 mg ORAL ANDA 32 sections